-
Beauty Health Stock Plunges After Q3 Print: Analysts Take A Deep Dive, Challenges 'More Than Skin Deep'
Tuesday, November 14, 2023 - 12:56pm | 544Beauty Health Co (NASDAQ: SKIN) shares tanked in early trading on Tuesday, after reporting downbeat quarterly results. The results came amid an exciting earnings season. Here are some key analyst takeaways from the earnings release. Benchmark On Beauty Health Analyst Bruce Jackson downgraded the...
-
Beauty Health Stock Hit With Downgrade At Stifel: What Investors Need To Know
Wednesday, June 21, 2023 - 10:58am | 481Amidst growing uncertainties and revised growth forecasts, Stifel Financial Corp (NYSE:SF) on Monday hit Beauty Health Co (NASDAQ:SKIN) with a downgrade, causing shares to sink more than 13% before a slight rebound. The SKIN Analyst: Jonathan Block downgraded Beauty Health from a Buy to a Hold...
-
Stifel Drops Bullish Zoetis Thesis After 108% Outperformance
Wednesday, August 22, 2018 - 9:40am | 414The bullish case for Zoetis Inc (NYSE: ZTS) has come to an end after the stock outperformed the S&P 500 index by 108 percent since spinning out from Pfizer Inc. (NYSE: PFE), according to Stifel. The Analyst Stifel's Jonathan Block downgraded Zoetis from Buy to Hold with a $95...
-
Inspire Medical Has $10B Annual Market Opportunity, Stifel Says In Bullish Initiation
Tuesday, May 29, 2018 - 10:48am | 329Not a month into Inspire Medical Systems Inc (NYSE: INSP)’s life as a publicly traded company, the Street is coming to consensus. Two bulls and a fence-sitter issued their opinions Tuesday. The Rating Stifel Nicolaus analyst Jonathan Block initiated coverage of Inspire with a Buy rating and...
-
Medtech Supplier IntriCon Rallies After Bullish Stifel Initiation
Tuesday, April 17, 2018 - 1:39pm | 384IntriCon Corporation (NASDAQ: IIN), a medical technology company and major supplier to Medtronic PLC (NYSE: MDT)'s diabetes division, is "one of the more interesting and undiscovered small-cap names" in its sector, according to Stifel. The Analyst Analyst Jonathan...
-
Stifel's Doctor Survey Triggers Glaukos Downgrade
Friday, April 13, 2018 - 9:27am | 364The bullish case for Glaukos Corp (NYSE: GKOS), a company focusing on designing products and procedures for the treatment of glaucoma, is based on expectations the company will stabilize its micro-invasive glaucoma surgery concomitant market share in 2019. But after speaking with dozens of doctors...
-
Pet Therapeutic Entyce Can Drive Aratana Higher, Stifel Says In Upgrade
Tuesday, March 27, 2018 - 12:10pm | 392Aratana Therapeutics Inc (NASDAQ: PETX), which has a portfolio treatments for pet diseases and disorders, is likely to ride high on product momentum, according to Stifel. The Analyst Analyst Jonathan Block upgraded shares of Aratana from Hold to Buy and raised the price target from $6 to $...
-
Patterson's Growth, Market Share At Risk In The Years Ahead
Thursday, July 6, 2017 - 2:32pm | 462Patterson Companies, Inc. (NASDAQ: PDCO), a distributor of consumable dental products and other services, is expected to see pressure in the coming years to its growth profile and market share take, according to analysts at Stifel. Stifel's Jonathan Block downgrades Patterson's stock rating from...
-
Align's New Direct-To-Consumer Focus Earns It A Higher Price Target From Stifel
Monday, November 28, 2016 - 1:20pm | 229Earlier this month, Invisalign maker Align Technology, Inc. (NASDAQ: ALGN) beat on both top- and bottom-line Q3 estimates, and shares have been up around 10 percent since. Stifel analyst Jonathan Block increased his price target for the stock from $95 to $110, representing a 15 percent upside from...
-
Stifel Initiates Coverage On Zoetis, Sets $58 Target
Wednesday, June 1, 2016 - 12:16pm | 178Stifel's Jonathan Block initiated coverage on Zoetis Inc (Nyse: ZTS) with a Buy rating and a price target of $58.00. Block estimated that "worldwide peak sales could reach $400 to $500 million versus management's estimate of > $300 million." He envisions the company will...
-
Stifel Sees Near-Term Concerns At Glaukos Overshadowing Long-Term Bullishness
Friday, April 8, 2016 - 9:36am | 378Jonathan Block of Stifel initiated coverage of ophthalmic medical technology company Glaukos Corp (NYSE: GKOS) with a Hold rating, saying near-term concerns overshadow long-term bullishness. "In the coming years, we expect Glaukos' total addressable market (TAM) to expand significantly as new...
-
Stifel: Appreciate The Beauty Of MonaLisa, Buy Cynosure
Monday, September 14, 2015 - 10:38am | 252Shares of Cynosure, Inc. (NASDAQ: CYNO) have risen 30 percent year-to-date. Stifel’s Jonathan Block has upgraded the rating on Cynosure from Hold to Buy, with a price target of $44. Block believes that the contribution of the MonaLisa Touch product to the company’s revenue...
-
Stifel Reiterates Rating, Raises Price Target On IDEXX Laboratories On Bullish Diligence
Friday, January 16, 2015 - 10:20am | 211In a report published Friday, Stifel analyst Jonathan Block reiterated a Buy rating on IDEXX Laboratories, Inc. (NASDAQ: IDXX), and raised the price target from $155.00 to $178.00. In the report, Stifel noted, “In our September 2014 diligence, we surveyed 110 veterinary practices to get a first...
-
UPDATE: Stifel Initiates Coverage on Zeltiq Aesthetics on Multiple Positive Factors
Thursday, March 20, 2014 - 9:23am | 131In a report published Thursday, Stifel analyst Jonathan Block initiated coverage on Zeltiq Aesthetics (NASDAQ: ZLTQ) with a Buy rating and $28.00 price target. In the report, Stifel noted, “We are initiating coverage of ZELTIQ Aesthetics, Inc. (ZLTQ) with a Buy rating and $28 target price. ZELTIQ...
-
UPDATE: Stifel Reiterates on Aratana Therapeutics Following Meetings with Multiple Companies
Monday, February 10, 2014 - 8:48am | 148In a report published Monday, Stifel analyst Jonathan Block reiterated a Buy rating on Aratana Therapeutics (NASDAQ: PETX), but lowered the price target from $33.00 to $30.00. In the report, Stifel noted, “Over the past couple of weeks we met with several companies in the burgeoning pet...